Patents by Inventor Gregg A. Hastings
Gregg A. Hastings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8017349Abstract: A human F-spondin-like protein and DNA (RNA) encoding such protein and a procedure for producing such protein by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for treating spinal cord injuries and damage to peripheral nerves by promoting neural-cell adhesion and neurite extension, inhibiting tumor metastases and tumor angiogenesis, and stimulating wound repair. Antagonists are also disclosed which may be utilized to prevent malaria. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.Type: GrantFiled: February 2, 2009Date of Patent: September 13, 2011Assignee: Human Genome Sciences, Inc.Inventors: Gregg A. Hastings, Patrick J. Dillon
-
Publication number: 20090311263Abstract: A human Vascular IBP-Like Growth Factor polypeptide (VIGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonist against such polypeptides and their use as a therapeutic to treat atherosclerosis, tumors and scarring are also disclosed. Diagnostic assays for identifying mutations in VIGF nucleic acid sequences and altered levels of the VIGF polypeptide are also disclosed.Type: ApplicationFiled: August 20, 2009Publication date: December 17, 2009Applicant: Human Genome Sciences, Inc.Inventors: Gregg A. Hastings, Craig A. Rosen
-
Publication number: 20090208974Abstract: A human F-spondin-like protein and DNA (RNA) encoding such protein and a procedure for producing such protein by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for treating spinal cord injuries and damage to peripheral nerves by promoting neural-cell adhesion and neurite extension, inhibiting tumor metastases and tumor angiogenesis, and stimulating wound repair. Antagonists are also disclosed which may be utilized to prevent malaria. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.Type: ApplicationFiled: February 2, 2009Publication date: August 20, 2009Applicant: Human Genome Sciences, Inc.Inventors: Gregg Hastings, Patrick J. Dillon
-
Publication number: 20090142329Abstract: Disclosed are human interleukin-1 ? converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.Type: ApplicationFiled: August 25, 2008Publication date: June 4, 2009Applicant: Human Genome Sciences, Inc.Inventors: Wei-Wu He, Craig A. Rosen, Peter L. Hudson, Gregg A. Hastings
-
Patent number: 7485459Abstract: A human F-spondin-like protein and DNA (RNA) encoding such protein and a procedure for producing such protein by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for treating spinal cord injuries and damage to peripheral nerves by promoting neural-cell adhesion and neurite extension, inhibiting tumor metastases and tumor angiogenesis, and stimulating wound repair. Antagonists are also disclosed which may be utilized to prevent malaria. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.Type: GrantFiled: March 1, 2004Date of Patent: February 3, 2009Assignee: Human Genome Sciences, Inc.Inventors: Gregg A. Hastings, Patrick J. Dillon
-
Publication number: 20080318835Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's, disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: February 29, 2008Publication date: December 25, 2008Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett, Gregg A. Hastings
-
Publication number: 20080317754Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: ApplicationFiled: June 1, 2007Publication date: December 25, 2008Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Publication number: 20080312146Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: ApplicationFiled: May 21, 2007Publication date: December 18, 2008Applicants: Human Genome Sciences, Inc., Beth Israel Deaconess Medical Center, SmithKline Beecham Corp.Inventors: Luisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
-
Patent number: 7416855Abstract: Disclosed are human interleukin-1 ? converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.Type: GrantFiled: March 17, 2004Date of Patent: August 26, 2008Assignee: Human Genome Sciences, Inc.Inventors: Wei-Wu He, Craig A. Rosen, Peter L. Hudson, Gregg A. Hastings
-
Publication number: 20080057510Abstract: A human Vascular IBP-Like Growth Factor polypeptide (VIGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonist against such polypeptides and their use as a therapeutic to treat atherosclerosis, tumors and scarring are also disclosed. Diagnostic assays for identifying mutations in VIGF nucleic acid sequences and altered levels of the VIGF polypeptide are also disclosed.Type: ApplicationFiled: August 30, 2007Publication date: March 6, 2008Applicant: Human Genome Sciences, Inc.Inventors: Gregg Hastings, Craig Rosen
-
Publication number: 20070259806Abstract: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.Type: ApplicationFiled: June 4, 2007Publication date: November 8, 2007Applicants: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Gregg Hastings, Timothy Coleman, Patrick Dillon, Daniel Lawrence, Maria Sandkvist, Manuel Yepes, Michael Wong
-
Publication number: 20070213255Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.Type: ApplicationFiled: October 17, 2006Publication date: September 13, 2007Applicants: Human Genome Sciences, Inc., The American National Red CrossInventors: Gregg Hastings, Gene Liau, Elena Tsifrina
-
Publication number: 20070203070Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: ApplicationFiled: May 4, 2007Publication date: August 30, 2007Applicant: Human Genome Sciences, Inc.Inventors: Craig Rosen, Steven Ruben, Yi Li, Zhizhen Zeng, Hla Kyaw, Carrie Fischer, Haodong Li, Daniel Soppet, Reiner Gentz, Ying-Fei Wei, Paul Moore, Paul Young, John Greene, Ann Ferrie, Gregg Hastings
-
Patent number: 7235371Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: July 21, 2005Date of Patent: June 26, 2007Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Patent number: 7220557Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: GrantFiled: August 13, 1999Date of Patent: May 22, 2007Assignees: Human Genome Sciences, Inc., Beth Israel-Deaconess Medical Center, SmithKline Beecham CorporationInventors: Gregg A. Hastings, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
-
Publication number: 20070026495Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: September 28, 2006Publication date: February 1, 2007Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Zdenka Jonak, Stephen Trulli, James Fornwald, Jonathan Terrett, Gregg Hastings
-
Publication number: 20070027084Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: September 28, 2006Publication date: February 1, 2007Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Zdenka Jonak, Stephen Trulli, James Fornwald, Jonathon Terrett, Gregg Hastings
-
Patent number: 7153670Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.Type: GrantFiled: October 8, 2004Date of Patent: December 26, 2006Assignees: Human Genome Sciences, Inc., The American Red CrossInventors: Gregg A. Hastings, Gene Liau, Elena Tsifrina
-
Patent number: 6994978Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: December 4, 2003Date of Patent: February 7, 2006Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Publication number: 20060024299Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: ApplicationFiled: July 21, 2005Publication date: February 2, 2006Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Gregg Hastings, Mark Adams, Claire Fraser, Norman Lee, Ewen Kirkness, Judith Blake, Lisa Fitzgerald, Fred Drake, Maxine Gowan